pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD
Acadia Pharmaceuticals
Acadia Pharmaceuticals B.V.
Acadia Pharmaceuticals is a pharma organization headquartered in Indianapolis, USA. It trades on NYSE under ticker ACAD. Primary therapeutic focus areas include Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Dis
Indianapolis, USA HQ
17 Employees
Public company Type
ACAD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Indianapolis, USA
- Employees
- 17
- Programs
- 32
- Drugs
- 15
- Patents
- 77
Pimavanserin 34 mg
Phase 2 · small molecule · Agitation and Aggression in Alzheimer's Disease
Pimavanserin 34 mg for Agitation and Aggression in Alzheimer's Disease is a Phase 2 program (small_molecule) at Acadia Pharmaceuticals B.V. with 1 ClinicalTrials.gov record(s).
Internal code ACP-103-032
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Acadia Pharmaceuticals B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Agitation and Aggression in Alzheimer's Disease
- Status
- terminated
- Trials
- 1